LOS ANGELES CAPITAL MANAGEMENT LLC
Position in LYEL — Lyell Immunopharma, Inc.
CIK 1177206
LOS ANGELES, CA
Position in LYEL
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$133,545
New position
Shares Held
9,505
first reported quarter
Ownership
0.039%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#55
of 87 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,466,927 across 167 Biotechnology names. LYEL ranks #95 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
729,635 | $219,642,024 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
1,938,035 | $151,689,999 | |
| 3 | CAI |
Caris Life Sciences, Inc.
|
3,958,531 | $70,541,022 | |
| 4 | INCY |
Incyte Corp
|
578,986 | $65,633,852 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
130,802 | $64,973,277 | |
| 6 | EXEL |
Exelixis, Inc.
|
1,159,457 | $63,086,055 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
98,585 | $61,471,690 | |
| 8 | RPRX |
Royalty Pharma plc
|
877,674 | $49,211,181 |
All Filings in LYEL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $133,545 | 9,505 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||